Opko Health’s (OPK) cost of revenues declined from $157.4 million in the second quarter of 2017 to $150.1 million in the second quarter of 2018. In the first half of 2018, its cost of revenues were $304.1 million compared to $312.2 million in the first half of 2017.
In the second quarter, it reported SG&A (selling, general, and administrative) expenses and R&D (research and development) expenses of $87.7 million and $29.2 million, respectively, compared to $105.5 million and $33.1 million, respectively, in Q2 2017.
In the first half of 2018, its cost of revenues declined to $304.1 million from $312.2 million in the first half of 2017.
In the first half of 2018, its SG&A and R&D expenses were $179.2 million and $62.1 million, respectively, compared to $215.5 million and $59.7 million, respectively, in the first half of 2017.
In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). The trial has enrolled 225 treatment-naïve children with GHD.
In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency.
In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1[1. glucagon-like peptide] and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.
Of the six analysts tracking Opko Health (OPK) in August, two have recommended a “strong buy,” and two have recommended a “buy” for the stock. One analyst has recommended a “hold,” and one has recommended a “sell.”
On August 8, Opko Health had a consensus 12-month target price of $12.10, which represents a ~120.4% return on investment over the next 12 months.
Of the 14 analysts tracking Ionis Pharmaceuticals (IONS) in August, ~29% of them have recommended a “buy” for the stock. Of the four analysts tracking Progenics Pharmaceuticals (PGNX), all four have recommended a “buy.” Of the nine analysts tracking Acadia Pharmaceuticals (ACAD), ~67% of them have recommended a “buy.”
In August, Ionis Pharmaceuticals, Progenics Pharmaceuticals, and Acadia Pharmaceuticals have consensus 12-month target prices of $57.42, $15, and $31.63, respectively. That represents ~26%, ~82.48%, and ~144.25% returns on investment, respectively, over the next 12 months.